How to Power Innovation and Efficiency with Attention to the Little Things

On There’s More to IT, host Jason Claybrook and guests will explore some foundational questions about the technology that’s driving us all forward.

Why do we build the stuff we build? What’s behind the scenes? Where are we falling short or putting revenue first?

The days of post-trade show drinks and conversation are far from over. In fact, they live right here on There’s More to IT.

 

The pace of technological innovation and adoption is quicker than it’s ever been. In fact, it’s likely fair to call it breakneck.

However, the rush of chasing the latest and greatest is no excuse to avoid the fundamentals. In fact, failing to pay attention to the little things is a recipe not only for stagnation, but for regression and wasted dollars.

On this episode of There’s More to IT, hosts Jason Claybrook, Simon Lok and Reid Estreicher dove into the overarching topic of new and exciting technologies – and how to ensure your organization is making the most of them.

Particularly for organizational leaders, choosing which new technologies have staying power worth investing in is critical. For example, parts of the world are using 16Hz internet, which is pending approval in American – once approved, will it make sense for most businesses to adopt it?

“If you talk about technology but don’t understand the science behind whats going on, every decision that you make will be flawed.” – Simon Lok

Ignoring the details of technology adoption, rollout and implementation, Claybrook said, is as good as “setting money on fire,” and that’s a price no organization can afford in a global landscape shifting faster than any period in recent memory.

Tune in to the entirety of this episode of There’s More to IT for more front-line insights about the drivers behind solid IT investments, examples that show the perils of making a wrong turn (or, in this case, writing the wrong check), and more.

Listen to Previous Episodes of There’s More to IT!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More